Ly3437943 (LY), a novel triple GIP/GLP-1/glucagon receptor agonist, provides glucose lowering and weight loss in patients with type 2 diabetes after 12 weeks of treatment
In this medfyle
The novel single peptide LY3437943, a triple agonist against GIP, GLP-1, and glucagon receptors, is characterized in this study to explore the overall safety and tolerability and the PK and PD profiles. In the 12-week Phase 1 multiple-ascending dose study the overall safety and tolerability was found to be similar to that of other agents in the incretin class, the PK profile supports once-weekly dosing, and the agent increases body weight loss.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a highlights summary of an oral session given at the EASD Annual Meeting 2022 and presented by:
Dr. Zvonko Milicevic
Eli Lilly and Company
Vienna, Austria
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
